Key Takeaways

• Medical Necessity: Gestational carrier (GC) arrangements are a specialized medical intervention used when a patient has a documented medical indication that makes pregnancy impossible or life-threatening, such as the absence of a uterus or serious medical contraindications.
• Low Prevalence but Steady Growth: GC pregnancies remain a small fraction of overall assisted reproductive technology (ART) usage, accounting for only 1.5% of cycles in 2022, though the total number of reported GC cycles has grown steadily from 1,539 in 2004 to 11,515 in 2023.
• Legal Fragmentation: The legal landscape in the United States is highly varied, with some states offering clear statutory frameworks for parentage while others prohibit compensated contracts, creating legal uncertainty for intended parents and carriers.

The provided sources outline the Clinical framework of Gestational Carrier use as a vital family-building option for those facing specific biological or medical challenges. Unlike traditional surrogacy, where the carrier uses her own egg, a gestational carrier has no genetic link to the child; the embryo is created via in vitro fertilization (IVF) using gametes from the intended parents or donors. This distinction is critical because modern statutory frameworks and clinical guidelines primarily focus on GC arrangements rather than the now-uncommon model of genetic surrogacy.

The Clinical framework of gestational carrier arrangements is strictly guided by the American Society for Reproductive Medicine (ASRM), which specifies that this path should be reserved for patients with clearly documented conditions. These include congenital absence of the uterus, uterine anomalies like Asherman syndrome, or medical conditions that would be severely exacerbated by pregnancy. Additionally, GC usage is recognized as essential healthcare for familial structures where gestation is biologically impossible, such as for single men or male same-sex couples.

Despite increased media visibility, data from the Centers for Disease Control and Prevention (CDC) and the Society for Assisted Reproductive Technology (SART) show that GC use is a specialized and relatively rare modality. National trends indicate that GC deliveries occurred at a rate of 13.7 per 100,000 nationwide between 2017 and 2020. While this statistic represents a 55% increase over that period, GC cycles still constitute less than 2% of all ART procedures.

There are unique obstetric risk profiles associated with GC pregnancies that policymakers must consider. Research indicates higher adjusted risks for placental abruption, low-lying placenta, and postpartum hemorrhage in GC pregnancies compared to non-GC pregnancies. Because of these risks, ASRM and SART strongly advocate for Single-Embryo Transfer (SET) to minimize the dangers associated with multiple gestations.

The legal environment for GC arrangements in the U.S. is "fractured." While states like Michigan and Massachusetts have recently enacted laws to protect IVF and clarify parentage pathways, other jurisdictions still treat compensated surrogacy contracts as void or unenforceable. This inconsistency can lead to ambiguous parentage at delivery and insurance coverage denials. ASRM emphasizes that an evidence-based Clinical framework of Gestational Carrier policy should protect the bodily autonomy of the carrier, ensure they have independent legal counsel, and provide a clear legal pathway for intended parents to be listed on birth certificates.

Ultimately, the sources argue that policy development should be driven by peer-reviewed data rather than anecdotes. Stakeholders are encouraged to craft narrow legislation that upholds clinical best practices, avoids unnecessary financial barriers, and protects the health of both the gestational carrier and the future child

Click Here to Read the Regulatory Overview